Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Pharmaceutical considerations in the use of tetrandrine to treat silicosis.

Authors
Ma-JK; Chao-H; Ma-JY; Hubbs-A; Castranova-V
Source
Silica and Silica-Induced Lung Diseases. Castranova V, Vallyathan V, Wallace WE, eds., Boca Raton, FL: CRC Press, 1995 Dec; :331-341
Link
NIOSHTIC No.
00240948
Abstract
This chapter reviewed the disadvantages of conventional oral tetrandrine (518343) therapy in the treatment of silicosis and considered the pharmaceutical strategy for improved therapeutic effects of tetrandrine. This strategy included use of multiple emulsions as a drug delivery system, tetrandrine emulsion, the effect of emulsin on drug cell interactions, the effect of tetrandrine on the oxygen consumption of alveolar macrophages (AM) at rest and in response to zymosan stimulation following 1 hour incubation, and the emulsion mediated tetrandrine activity in-vivo. Studies suggested that tetrandrine effectively inhibits the macrophage orchestrated inflammatory process in response to silica (14808607) exposure and the subsequent fibrotic development. Data indicated that tetrandrine protects lung cells from silica toxicity and stimulation and restores healthy AM populations even after the drug has been eliminated from the pulmonary region. Tetrandrine water/oil/water emulsion was consistently more efficacious than the solution dosage form in the treatment of silica induced granulomatous pneumonia and alveolar lipoproteinosis in rats. Studies have demonstrated that early drug treatment following silica exposure may delay the fibrotic process by inhibiting abnormal cellular activity prior to the fibrotic event and restoring normal cell functions, thus allowing time for the lung to clear its dust problem. A delay or inhibition of the fibrotic process may have a very significant effect on development of the disease.
Keywords
NIOSH-Author; NIOSH-Cooperative-Agreement; Pulmonary-system-disorders; Medical-treatment; Lung-irritants; Lung-disease; Respiratory-system-disorders; Silica-dusts; Silicosis; Lung-cells; Laboratory-animals
CAS No.
518-34-3; 14808-60-7
Publication Date
19951220
Document Type
Book or book chapter
Editors
Castranova-V; Vallyathan-V; Wallace-WE
Funding Amount
2937066
Funding Type
Cooperative Agreement; Grant
Fiscal Year
1996
NTIS Accession No.
NTIS Price
ISBN No.
0849347092
Identifying No.
Cooperative-Agreement-Number-U60-CCU-306149; 1195142-5430
NIOSH Division
DRDS
Priority Area
Pulmonary-system-disorders
Source Name
Silica and Silica-Induced Lung Diseases
State
NY; DC
Performing Organization
Center to Protect Workers' Rights
TOP